EpCAM ‐Targeted Erlotinib Delivery: Enhancing Nasopharyngeal Carcinoma Treatment With Polyethylene Glycol‐Coated Graphene Oxide
Head & Neck · 2025
DOI: 10.1002/hed.28122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Chien-Fu Yeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Polyethylene Glycols, Nasopharyngeal Carcinoma, Graphite, Epithelial Cell Adhesion Molecule. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Ministry of Science and Technology, National Science and Technology Council (Taiwan), Ministry of Science and Technology, Government of the People’s Republic of Bangladesh.
Abstract (Originalsprache)
Background
Recently, graphene oxide (GO) has attracted significant attention as a potential innovative vehicle for the delivery of anticancer agents. In this study, we aimed to evaluate whether functionalized GO, known as epithelial cell adhesion molecule (EpCAM)‐targeted polyethylene glycol (PEG)‐coated GO (GO‐PEG‐EpCAM), could be used as a therapeutic agent against nasopharyngeal carcinoma (NPC) and to identify its underlying molecular mechanisms.
Methods
We used NPC cells to assess the anticancer effects of GO‐PEG‐EpCAM/erlotinib in vitro and in vivo. Employing RNA sequencing and Ingenuity Pathway Analysis (IPA), we sought to elucidate the molecular pathways through which GO‐PEG‐EpCAM/erlotinib affects NPC cells.
Results
Our findings revealed that GO‐PEG‐EpCAM/erlotinib reduced NPC cell viability and decreased invasion and migration abilities. An in vivo study further corroborated the anticancer potential of GO‐PEG‐EpCAM/erlotinib. Our comprehensive RNA sequencing analysis highlighted several molecular mechanisms underlying the anticancer effects of GO‐PEG‐EpCAM/erlotinib.
Conclusions
GO‐PEG‐EpCAM/erlotinib could be a potential therapeutic strategy for NPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Institute of Materials Science and Engineering, National Central University, Taoyuan, Taiwan.
- Department of Otolaryngology-Head and Neck Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
- School of Medicine, Tzu Chi University, Hualien, Taiwan.
- Department of Neurosurgery, Chang Gung Memorial Hospital Linkuo Medical Center and College of Medicine, Chang Gung University, Taoyuan, Taiwan.
ORCID-Profile: Ming-Ying Lan
Förderung
- Ministry of Science and Technology
- National Science and Technology Council (Taiwan)
- Ministry of Science and Technology, Government of the People’s Republic of Bangladesh
Zitieren
APA
Yeh, C. F., Lee, S. W., Liu, C. H., Hsu, Y. B., Lan, M. C., Lu, Y. J., Chen, J. P., & Lan, M. Y. (2025). EpCAM ‐Targeted Erlotinib Delivery: Enhancing Nasopharyngeal Carcinoma Treatment With Polyethylene Glycol‐Coated Graphene Oxide. Head & Neck. https://doi.org/10.1002/hed.28122
Vancouver
Yeh CF, Lee SW, Liu CH, Hsu YB, Lan MC, Lu YJ, et al. EpCAM ‐Targeted Erlotinib Delivery: Enhancing Nasopharyngeal Carcinoma Treatment With Polyethylene Glycol‐Coated Graphene Oxide. Head & Neck. 2025. doi:10.1002/hed.28122
BibTeX
@article{Yeh2025,
author = {Yeh, Chien-Fu and Lee, Sheng-Wei and Liu, Chin-Hsuan and Hsu, Yen-Bin and Lan, Ming-Chin and Lu, Yu-Jen and Chen, Jyh-Ping and Lan, Ming-Ying},
title = {EpCAM ‐Targeted Erlotinib Delivery: Enhancing Nasopharyngeal Carcinoma Treatment With Polyethylene Glycol‐Coated Graphene Oxide},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.28122}
}
EUVIMED